A federal appeals court has handed Louisiana a major victory in its fight against the FDA’s controversial 2023 abortion pill regulation, reinstating in-person medical requirements that the agency removed based on what even the FDA admits was inadequate safety data.
Story Snapshot
- Fifth Circuit blocks FDA’s 2023 telemedicine rule for mifepristone, requiring in-person doctor visits
- Louisiana challenged the regulation citing flawed safety studies and illegal abortions violating state law
- FDA conceded its remote safety study was inadequate but opposed reinstating restrictions
- Case expected to reach Supreme Court rapidly, potentially affecting nationwide abortion pill access
Court Overrules FDA on Safety Protocols
On May 1, 2026, a Fifth Circuit Court of Appeals panel granted Louisiana’s emergency stay request, blocking the FDA’s 2023 regulation that permitted mifepristone abortion pills to be prescribed via telemedicine and mailed to patients without in-person medical evaluations. The ruling reverses a district court decision that found Louisiana likely to succeed on the merits but denied the stay based on equitable considerations. The appeals court’s order reinstates the requirement for in-person doctor visits while keeping the drug available on the market under earlier protocols.
FDA Admits Data Problems in Own Defense
Louisiana’s lawsuit under the Administrative Procedure Act revealed troubling gaps in the federal agency’s decision-making process. The FDA conceded during litigation that its safety study supporting remote prescribing was inadequate, yet continued to oppose reinstating the in-person requirement while conducting what it claimed was an ongoing review. This admission raises serious questions about whether unelected bureaucrats prioritized ideology over rigorous safety standards. For Americans frustrated with government agencies that seem unaccountable to the people they serve, this case exemplifies how regulatory overreach can proceed even when the agency itself acknowledges its evidence is insufficient.
5th Circuit Panel Blocks 2023 Mifepristone Telemedicine Approval. This case will go to the Supreme Court very quickly. https://t.co/ODnnGiFvFG
— Josh Blackman (@JoshMBlackman) May 1, 2026
State Documents Medicaid Costs and Illegal Procedures
Louisiana presented evidence that the FDA’s telemedicine policy enabled illegal abortions in violation of state law and imposed measurable financial harm through increased Medicaid costs from complications. The state documented that the 2023 rule, implemented after the Supreme Court’s Dobbs decision returned abortion regulation to the states, directly undermined Louisiana’s ability to enforce its laws protecting unborn life. The district court agreed Louisiana faces irreparable harm and will likely prove the FDA acted arbitrarily and capriciously by relying on flawed or nonexistent data, though it initially denied the stay based on broader public interest arguments that the Fifth Circuit rejected.
Telemedicine Expansion Faces Legal Reckoning
The 2023 FDA rule removed in-person dispensing requirements that had been in place since mifepristone’s 2000 approval, a change that significantly expanded medication abortion access via telehealth following the Dobbs decision. Legal analysts expect this case to reach the Supreme Court quickly, where the justices could impose nationwide restrictions reversing recent telemedicine gains. This litigation differs from the 2023-2024 Alliance for Hippocratic Medicine case, which challenged earlier FDA approvals; Louisiana’s suit specifically targets the remote prescribing protocol based on the agency’s admitted failure to conduct proper safety studies for telemedicine use.
Implications for Federal-State Power Balance
The Fifth Circuit’s decision highlights growing judicial skepticism of federal agencies that bypass rigorous review processes, particularly when their actions conflict with state laws enacted through democratic processes. By granting the stay pending appeal, the court signaled that Louisiana’s challenge to agency overreach deserves expedited consideration. The ruling does not remove mifepristone from the market but restores earlier safeguards requiring medical professionals to evaluate patients in person before dispensing the drug. Whether the Supreme Court ultimately sides with Louisiana’s emphasis on safety protocols and state sovereignty or the FDA’s push for expanded access will shape abortion policy and federal regulatory power for years to come, affecting the millions of Americans on both sides who feel government institutions no longer serve their interests.
Sources:
5th Circuit Panel Blocks 2023 Mifepristone Telemedicine Approval – Inkl
5th Circuit Panel Blocks 2023 Mifepristone Telemedicine Approval – Reason
Alliance for Hippocratic Medicine v. FDA – Fifth Circuit Opinion
Statement on 5th Circuit Ruling on Mifepristone with Restrictions to Access – NPWH
